PSY34 What Do Public DATA Sources Tell US about Systemic LUPUS Erythematosus in Brazil?

Abstract

Systemic lupus erythematosus (SLE), a severe autoimmune disease, substantially impacts patients’ lives due to disease activity and treatment side effects. This research aims to describe the impact of SLE in Brazil. Open data were obtained from the Brazilian Hospital Information System (2009–2019) and Mortality Information System (2009–2018). Robotic process automation was used to convert data from both information systems into an SQLite-compatible format. Data extraction was performed for ICD-10 M32 and its subtypes using a Structured Query Language. Analyses were performed for mortality, hospitalization frequency and hospitalization costs in Brazilian reais (BRL). The exchange rate varied from 1 USD = 2.37 BRL (2009) to 3.73 BRL (2019). In 2018, 1,008 SLE-related deaths occurred in Brazil (3/day), representing a 19% increase compared with 2009 (844 deaths). Furthermore, the number of in-hospital SLE-related deaths increased 11-fold from 5 in 2009 to 56 in 2019. The mean annual growth in the total number of hospitalizations was 14.8%, and for admission to an intensive care unit (ICU) was 52.9%. A mean of 19% of hospitalizations were paediatric (0–17 years) patients. The number and total cost of SLE-related hospitalizations increased 4.5- and 6-fold, respectively (2009 vs 2019: 573 vs 2,611; USD 82,362.97 vs 501,368.11). The number and cost of ICU admissions increased from 2009 to 2019, with 3 versus 111 admissions (37-fold increase) and USD 8,003.44 versus 118,499.27 (14-fold increase), respectively. In 2019, ICU costs represented 24% of the total hospitalization costs. The mean total length of hospital stay was 17 days (9 days inpatient treatment, 8 ICU). In contrast to other countries, the annual number of SLE-related hospitalizations and deaths in Brazil has grown over the last 10 years. These data highlight an unmet need to improve SLE management in Brazil.